Critical Illness, Severe Sepsis
Conditions
Keywords
near infrared spectroscopy, tissue oxygenation, organ dysfunction, mortality
Brief summary
The purpose of this study is to evaluate the usefulness of an optimization of muscle perfusion and oxygenation, as assessed by the NIRS technique, in critically ill patients with sepsis.
Detailed description
The systemic inflammatory response to sepsis may cause impaired tissue oxygenation that can persist despite the restoration of a normal hemodynamic profile and systemic oxygen transport. Therefore, the assessment of tissue oxygenation and perfusion is recommended in patients with severe sepsis. The InSpectra tissue spectrometer relies on continuous wave near infrared (NIR) technology to estimate non invasively local tissue hemoglobin oxygen saturation in tissue (% StO2). This technology had been tested in a variety of systems: standard theoretical models of light transport, isolated blood, isolated blood-perfused animal organs and healthy human volunteers with induced limb ischemia. In critical-care medicine, NIRS has also been used to evaluate muscle oxygenation in trauma resuscitation and in lower extremity and abdominal compartment syndrome. However, NIRS has been rarely utilised to measure tissue blood flow and oxygen uptake in critically ill patients.
Interventions
resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
resuscitation will be based according to Surviving Sepsis Campaign
Sponsors
Study design
Eligibility
Inclusion criteria
* Two of four criteria for the systemic inflammatory response syndrome; and one of the following: * systolic blood pressure =\< 90 mm Hg; or * a blood lactate concentration =\> 4 mmol/l; or * skin marbling; or * impaired consciousness; or * urine output \< 30 ml/h.
Exclusion criteria
* Age \< 18 years * Pregnancy * Do-not-resuscitate status * Advanced directives restricting implementation of the protocol * Obesity (body mass index \[BMI\] \> 30) * Anasarca
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A combined endpoint of mortality and sequential organ failure assessment (SOFA) score increase at day 7 is the primary efficacy endpoint | Day 7 |
Secondary
| Measure | Time frame |
|---|---|
| duration of mechanical ventilation | from randomization to Day 28 |
| length of the hospital stay | from randomization to Day 90 |
Countries
France, Germany, Greece, Spain